HCV structure and genotypes

HCV Structure - The Viral Blueprint

• Family: Flaviviridae.

• Genome: Enveloped, single-stranded, positive-sense RNA (+ssRNA).

• Translation: Utilizes an Internal Ribosome Entry Site (IRES) for cap-independent translation within the host cell cytoplasm.

• Proteins Encoded: A single polyprotein is cleaved into:

  • Structural Proteins: Form the virion.
    • Core (C): Capsid protein.
    • Envelope (E1, E2): Glycoproteins for entry.
  • Non-Structural (NS) Proteins: For replication.
    • NS2 to NS5B: Includes protease, helicase, and RNA-dependent RNA polymerase (NS5B), a key drug target.

⭐ The high variability of the E2 glycoprotein's Hypervariable Region 1 (HVR1) is a key mechanism for immune evasion and persistence.

HCV Genotypes - A Diverse Family

• Genetic Heterogeneity: HCV is classified into 6 major genotypes (1-6) and numerous subtypes (e.g., 1a, 1b), which differ by >30% at the nucleotide level.

  • Genotype 1 is the most common in the United States.

• Quasispecies Concept: The virus exists as a dynamic swarm of related but distinct variants in a single patient.

  • This arises because the viral RNA-dependent RNA polymerase (NS5B) is error-prone and lacks proofreading capacity.
  • This genetic diversity allows the virus to evade the host immune system and contributes to the development of antiviral resistance.

⭐ Genotype 3 is most strongly associated with the development of hepatic steatosis and has a higher risk of accelerated fibrosis and hepatocellular carcinoma (HCC).

Clinical Relevance - Why Genotypes Matter

HCV genotyping is critical for tailoring antiviral therapy and maximizing cure rates (SVR). The choice between pangenotypic and genotype-specific regimens hinges on the specific viral genotype identified.

• Treatment Guidance: Genotype determines the optimal Direct-Acting Antiviral (DAA) regimen and duration.
• Pangenotypic Regimens: Effective across all major genotypes (1-6).
  • Examples: Glecaprevir/Pibrentasvir, Sofosbuvir/Velpatasvir.
  • Simplifies the treatment decision process, especially when testing is unavailable.
• Resistance: Pre-existing Resistance-Associated Substitutions (RASs) can lead to DAA failure. RAS testing may be considered, especially in treatment-experienced patients.

⭐ The presence of cirrhosis, prior treatment history, and specific genotype are the three most critical factors guiding the selection and duration of modern DAA regimens.

• HCV is an enveloped, single-stranded, positive-sense RNA virus from the Flaviviridae family.
• Lacks a proofreading 3'-5' exonuclease in its RNA polymerase (NS5B), leading to high mutation rates.
• This genetic instability results in multiple quasispecies within a single host, aiding immune evasion.
• There are at least 6 major genotypes; Genotype 1 is the most common in the U.S.
• Genotype is crucial for predicting response to and guiding the choice of direct-acting antiviral (DAA) therapy.